25/08/2026
China is entering a new phase of growth driven by robotics, artificial intelligence, and innovative medicines.
Among these sectors, innovative drugs are attracting strong global interest. In the first three months of 2026, overseas licensing deals involving Chinese innovative medicines reportedly exceeded USD 60 billion, close to half of the total value recorded in 2025.
This rapid growth shows that global investors and pharmaceutical companies are paying more attention to China’s biotech sector. Chinese biotech assets may now be entering a new stage of global value recognition.
China’s innovation economy is creating major opportunities in technology, healthcare, and advanced industries.